MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil

Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.

Episode metadata supplied by the publisher feed · Published Oct 28, 2022

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil

0:00 13:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 13 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on October 28, 2022.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!